Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

计划入组 42 人 · 首次发布于 2019 年 5 月 16 日

Non Invasive IDentification of Gliomas With IDH1 Mutation

计划入组 6 人 · 首次发布于 2012 年 10 月 11 日

Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

计划入组 220 人 · 首次发布于 2011 年 6 月 29 日

2-hydroxyglutarate-treated T-cell therapy

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Rigel Pharmaceuticals Initiates Phase Ib/II Trial of REZLIDHIA Combination Therapy for mIDH1 AML

Vorasidenib Shows Sustained Benefit in IDH-Mutant Low-Grade Glioma

Vorasidenib Shows Promise as First Targeted Therapy for IDH-Mutant Low-Grade Gliomas